Thanks for signing up for DividendStocks.com! It's the daily newsletter built for dividend and income investors. Before we can begin sending your daily updates, there’s one quick step left. Please confirm your subscription using the link below so our emails reach your inbox. Click Here to Confirm Your Subscription to DividendStocks.com Here’s a small glimpse of what you’ll get access to: Dividend Stock Ideas — Each newsletter features dividend stocks with high yields, sustainable payouts, and strong growth potential. Ex-Dividend Stocks — Want to capture upcoming dividend payouts? Find out which stocks are going ex-dividend this week. Market News and Events — Stay in the loop on the latest developments impacting popular dividend names like AT&T, Exxon Mobil, IBM, Procter & Gamble, and Verizon. Bonus: As a thank-you for confirming, you’ll also receive a free PDF copy of Automatic Income, our popular guide to building wealth through dividend investing. Let’s get your dividend journey started! Discover Top Income-Generating Stocks Here See you in your inbox soon,
The DividendStocks.com Team P.S. Don’t miss out click here to verify your subscription and secure your daily dividend insights and your free investing guide!
This Month's Bonus Content 3 Stocks Under $5 With Strong Analyst Upside PotentialBy Chris Markoch. Article Published: 2/24/2026. 
Key Points - Grab Holdings is gaining analyst support as revenue growth and its first full year of profitability highlight long-term opportunity in Southeast Asia’s expanding digital economy.
- Vaxart offers speculative biotech upside with its oral vaccine platform targeting influenza, norovirus, and COVID-19, creating a high-risk, high-reward setup.
- ThredUp is positioned to benefit from the fast-growing resale market, with strong institutional ownership and industry forecasts pointing to sustained secondhand demand.
- Special Report: [Sponsorship-Ad-6-Format3]
While many investors are rotating out of speculative penny stocks, others continue to embrace the risk-reward dynamic. Stocks that trade for under $5 carry meaningful risk: many issuers are unprofitable, and some generate little to no revenue. These are generally small-cap companies, a group that has been under pressure in recent years. Even though the Russell 2000 has shown some signs of recovery, that improvement has not been uniform across the broader small-cap sector. While headlines focus on Tesla's car sales, tech analyst Jeff Brown says the real story is Tesla's role in a $25 trillion AI revolution — one that Nvidia's CEO himself has called a "multi-trillion-dollar future industry" — and he's uncovered a little-known stock 168 times smaller than Nvidia that could be positioned to ride this breakthrough. Click here now to see the full report That could change in 2026 if the economic outlook improves, as money may start to flow back into speculative names. As always, quality matters when navigating this part of the market. One way to screen for higher-quality opportunities is to look for stocks with positive analyst sentiment. The three names below each let investors establish a sizable position with a relatively modest outlay while offering the potential for meaningful upside over the next five years. Profitability Milestone Meets Long-Term Emerging Market Growth Emerging market equities are expected to be among the winners in 2026, a trend that hasn’t yet benefited Grab Holdings Inc. (NASDAQ: GRAB), which is down roughly 15% this year. Headquartered in Singapore, Grab operates a super app that blends technology, e-commerce and fintech services. One driver of the recent pullback is its proposed merger with Indonesian ride-hailing competitor GoTo. The deal remains unsettled and could face significant legislative changes in Indonesia that would constrain the company’s earnings potential there. The company also missed revenue expectations in its Q4 2025 earnings report. For context, revenue rose 19% year over year, and the year represented the company’s first full year of profitability. Analysts are forecasting roughly 120% earnings growth over the next 12 months. That helps explain why sentiment remains constructive. GRAB shares have a consensus price target of $6.47, which would represent about 54% upside from their price at the time of writing. High-Risk Biotech With Platform Potential Penny stock investors often look to the biotechnology sector to balance risk and reward. One name to watch is Vaxart Inc. (OTCMKTS: VXRT), the only company on this list that meets the classic definition of a penny stock. At the time of writing, VXRT traded at just over $0.60 per share. VXRT does not have extensive analyst coverage, but the one analyst who rated it in the past 12 months issued a Buy with a $2 price target. It’s common for analysts to overlook some biotech firms. Vaxart is a clinical-stage company, meaning its candidates are still in clinical trials. The potential upside is straightforward: Vaxart is developing oral vaccines for influenza, norovirus and COVID-19. Beyond convenience and reducing needle-related anxiety, the company says its platform may elicit a broader immune response that could provide wider protection. Institutional ownership is only about 18%, but, by dollar volume, inflows have outpaced outflows nearly 10-to-1, which is notable for a microcap biotech. Resale Tailwinds Could Turn Today’s Losses Into Tomorrow’s Gains ThredUp Inc. (NASDAQ: TDUP) is down about 33% in 2026, but a broader look is instructive: TDUP is up more than 66% over the past 12 months, suggesting the recent decline may be a normal pullback as investors shy away from unprofitable companies. In ThredUp’s case, it’s important to qualify that with "yet." The company runs an online consignment and thrift platform that has gained traction with Gen Z, reflected in revenue growth. In its most recent quarter, revenue rose 12.5% year over year. ThredUp cites a GlobalData 2025 market survey projecting the U.S. secondhand market’s gross merchandise value will grow at a compound annual growth rate of about 9% through 2029. Institutional investors own roughly 89% of the stock. Buying has outpaced selling about two-to-one by dollar volume and roughly three-to-one by number of trades. That said, short interest is around 17%, which adds to near-term volatility. The consensus price target from six analysts is $12.50, implying more than 190% upside from the stock’s price at the time of writing.
| 
